Vaccines:Article Title: Form 10-Q
Article Snippet: In the fourth quarter of 2011, Biogen Idec SRLreceived a notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) stating that sales of TYSABRI for the period from February 2009 through February 2011 exceeded by Euro 30.7million a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in February 2007.
Article Title: Ex-99.1 Press Release dated November 23, 2004
Article Snippet: “TYSABRI is a powerful and innovative therapy that offers new hope for hundreds of thousands of people living with MS,” said James C. Mullen, chief executive officer, Biogen Idec.
Article Title: Form 10-Q
Article Snippet: Table of Contents In the fourth quarter of 2011, Biogen Idec SRLreceived a notice from the Italian National Medicines Agency (AIFA) stating that sales of TYSABRI for the period from February 2009 through February 2011 exceeded by Euro 30.7million a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in February 2007.
Article Title: Form 10-Q
Article Snippet: In the fourth quarter of 2011, Biogen Idec SRLreceived a notice from the Italian National Medicines Agency (AIFA) stating that sales of TYSABRI for the period from February 2009 through February 2011 exceeded by Euro 30.7million a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in February 2007.
Article Title: Form 10-Q
Article Snippet: 40 Table of Contents In the fourth quarter of 2011, Biogen Idec SRLreceived a notice from the Italian National Medicines Agency (AIFA) stating that sales of TYSABRI for the period from February 2009 through February 2011 exceeded by Euro 30.7million a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in February 2007.
Expressing:Article Title: Form 10-Q
Article Snippet: In the fourth quarter of 2011, Biogen Idec SRLreceived a notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) stating that sales of TYSABRI for the period from February 2009 through February 2011 exceeded by Euro 30.7million a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in February 2007.
Article Title: Ex-99.1 Press Release dated November 23, 2004
Article Snippet: “TYSABRI is a powerful and innovative therapy that offers new hope for hundreds of thousands of people living with MS,” said James C. Mullen, chief executive officer, Biogen Idec.
Article Title: Form 10-Q
Article Snippet: Table of Contents In the fourth quarter of 2011, Biogen Idec SRLreceived a notice from the Italian National Medicines Agency (AIFA) stating that sales of TYSABRI for the period from February 2009 through February 2011 exceeded by Euro 30.7million a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in February 2007.
Article Title: Form 10-Q
Article Snippet: In the fourth quarter of 2011, Biogen Idec SRLreceived a notice from the Italian National Medicines Agency (AIFA) stating that sales of TYSABRI for the period from February 2009 through February 2011 exceeded by Euro 30.7million a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in February 2007.
Article Title: Form 10-Q
Article Snippet: 40 Table of Contents In the fourth quarter of 2011, Biogen Idec SRLreceived a notice from the Italian National Medicines Agency (AIFA) stating that sales of TYSABRI for the period from February 2009 through February 2011 exceeded by Euro 30.7million a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in February 2007.
Control:Article Title: Form 10-Q
Article Snippet: In the fourth quarter of 2011, Biogen Idec SRLreceived a notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) stating that sales of TYSABRI for the period from February 2009 through February 2011 exceeded by Euro 30.7million a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in February 2007.
Article Title: Ex-99.1 Press Release dated November 23, 2004
Article Snippet: “TYSABRI is a powerful and innovative therapy that offers new hope for hundreds of thousands of people living with MS,” said James C. Mullen, chief executive officer, Biogen Idec.
Article Title: Form 10-Q
Article Snippet: Table of Contents In the fourth quarter of 2011, Biogen Idec SRLreceived a notice from the Italian National Medicines Agency (AIFA) stating that sales of TYSABRI for the period from February 2009 through February 2011 exceeded by Euro 30.7million a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in February 2007.
Article Title: Form 10-Q
Article Snippet: In the fourth quarter of 2011, Biogen Idec SRLreceived a notice from the Italian National Medicines Agency (AIFA) stating that sales of TYSABRI for the period from February 2009 through February 2011 exceeded by Euro 30.7million a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in February 2007.
Article Title: Form 10-Q
Article Snippet: 40 Table of Contents In the fourth quarter of 2011, Biogen Idec SRLreceived a notice from the Italian National Medicines Agency (AIFA) stating that sales of TYSABRI for the period from February 2009 through February 2011 exceeded by Euro 30.7million a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in February 2007.
| 